Table 2

Reclassification and discrimination statistics (95% CI) for 10-year risk of the primary outcome (fatal and nonfatal HF, CHD, or stroke) by circulating cardiac biomarkers among ARIC participants with diabetes

C statisticIDINRI
Model 20.668 (0.645–0.691)
Model 2 + hs-TnT0.687 (0.665–0.709) (P = 0.001)0.04 (0.02–0.06) (P < 0.001)0.11 (0.03–0.18) (P = 0.007)
Model 2 + NTproBNP0.682 (0.659–0.704) (P = 0.009)0.02 (0.01–0.04) (P < 0.001)0.11 (0.04–0.17) (P = 0.013)
Model 2 + hs-TnT and NTproBNP0.694 (0.672–0.716) (P < 0.001)0.05 (0.03–0.08) (P < 0.001)0.20 (0.11–0.26) (P < 0.001)
Model 30.688 (0.665–0.710)
Model 3 + hs-TnT0.698 (0.676–0.720) (P = 0.018)0.02 (0.01–0.04) (P < 0.001)0.07 (0.00–0.15) (P = 0.06)
Model 3 + NTproBNP0.694 (0.672–0.716) (P = 0.08)0.01 (0.00–0.02) (P < 0.001)0.09 (0.03–0.16) (P = 0.013)
Model 3 + hs-TnT and NTproBNP0.703 (0.681–0.725) (P = 0.004)0.03 (0.02–0.05) (P < 0.001)0.16 (0.07–0.22) (P < 0.001)
  • Model 2 adjusted for age, sex, race, center, smoking status, log-transformed pack-years of cigarettes (packs of cigarettes smoked per day times number of years smoked), BMI, waist-to-hip ratio, mean systolic blood pressure, hypertension medication use, lipid-lowering medication use, aspirin use, education level, total-to-HDL cholesterol ratio, log-transformed triglycerides, and duration of disease. Model 3 adjusted for variables in model 2 plus ECG abnormalities and conventional complications of diabetes (retinopathy, nephropathy, PAD).